Alnylam Pharmaceuticals Inc banner

Alnylam Pharmaceuticals Inc
XMUN:DUL

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
XMUN:DUL
Watchlist
Price: 190.4 EUR -1.35%
Market Cap: €14.7B

Wall St Price Targets

DUL Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast DUL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DUL is 357.68 EUR with a low forecast of 204.58 EUR and a high forecast of 523.4 EUR.

Lowest Forecast
Price Target
204.58 EUR
7% Upside
Average Forecast
Price Target
357.68 EUR
88% Upside
Highest Forecast
Price Target
523.4 EUR
175% Upside
Alnylam Pharmaceuticals Inc Competitors:
Price Targets
TCPC
BlackRock TCP Capital Corp
11% Upside
UFPT
UFP Technologies Inc
5% Upside
FBIZ
First Business Financial Services Inc
8% Upside

Revenue
Forecast

36% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
36% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 18%.

Gross Profit
Forecast

N/A
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

The compound annual growth rate for Gross Profit over the next 8 years is 19%.

Operating Income
Forecast

N/A
Past Growth
37% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
37% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

The compound annual growth rate for Operating Income over the next 8 years is 37%.

Pre-Tax Income
Forecast

N/A
Past Growth
92% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
N/A
Past Growth
92% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

The compound annual growth rate for Pre-Tax Income over the next 3 years is 92%.

Net Income
Forecast

N/A
Past Growth
40% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
40% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

The compound annual growth rate for Net Income over the next 8 years is 40%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is DUL's stock price target?
Price Target
357.68 EUR

According to Wall Street analysts, the average 1-year price target for DUL is 357.68 EUR with a low forecast of 204.58 EUR and a high forecast of 523.4 EUR.

What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
18%

Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 18%.

What is the Gross Profit forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
19%

The compound annual growth rate for Gross Profit over the next 8 years is 19%.

What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
37%

The compound annual growth rate for Operating Income over the next 8 years is 37%.

What is the Pre-Tax Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
92%

The compound annual growth rate for Pre-Tax Income over the next 3 years is 92%.

What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
40%

The compound annual growth rate for Net Income over the next 8 years is 40%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett